Evidence map›Paper›PMID 33685462›Full record

ArticleCancer cell international2021

Identification and characterization of a subpopulation of CD133

Jiuping Gao, Ting Yang, Xu Wang, Yi Zhang, Jing Wang, Beilei Zhang, Dihong Tang, Yanqiong Liu, Ting Gao, Qiuhui Lin and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jiuping GaoDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Ting YangDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Xu WangDepartment of Gynecology and Obstetrics, Xiangya Hospital Central South University, Changsha, China.
Yi ZhangDepartment of Gynecology and Obstetrics, Xiangya Hospital Central South University, Changsha, China.
Jing WangDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Beilei ZhangDepartment of Gynecology and obstetrics, The second people's Hospital of Hunan Province, Changsha, China.
Dihong TangDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Yanqiong LiuDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Ting GaoDepartment of Gynecology and obstetrics, Central Hospital of Yiyang City, Yiyang, Hunan Province, China.
Qiuhui LinDepartment of Gynecology and Obstetrics, The First People's Hospital of Shaoguang, Shaoguan, Guangdong Province, China.
Jun TangDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Jingting CaiDepartment of Gynecological Oncology, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China. 405247164@qq.com.ORCID http://orcid.org/0000-0002-6728-9326
Central South University · CNSecond People Hospital of Hunan · CN

Funding

National Natural Science Foundation of China 81472433natural science foundation of Hunan Province 2018JJ6109
6 · The paper itself

Abstract

backgroundUterine leiomyosarcoma (ULMS) is a malignant tumor found in the smooth muscle lining the walls of the uterus. Cancer stem cells (CSCs) are responsible for metastasis, drug resistance, and relapse of cancer, resulting in treatment failure. However, little is known about CSCs and their associated-markers in ULMS. We aimed to characterize and identify a subpopulation of CD133

methodsSK-UT-1 cells were sphere-forming cultured in vitro. We also sorted the CD133

resultsThe fourth-passage spheres were defined as a CD133

conclusionsCollectively, our findings indicated that CD133 may be a significant marker for cancer stem-like cells, and it may be a potential therapeutic target for human ULMS.

Indexed as

Cancer stem cellsCD133Drug resistanceTumorspheresUterine leiomyosarcoma

Identifiers

PMID33685462
PMCPMC7938532
OpenAlexW3135112661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.